Patents by Inventor Qian Ye
Qian Ye has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240097272Abstract: A gas-exhausting apparatus includes a gas-exhausting body and a gas-exhausting mechanism. The gas-exhausting mechanism includes a connecting assembly and a gas-ventilating member. The connecting assembly includes first and second connecting members. The first connecting member is provided with a first through hole for communicating with an inside of the battery cell. The second connecting member is provided with a second through hole for communicating with an outside of the battery cell. The first connecting member is configured to attach to a surface of the gas-ventilating member facing the inside of the battery cell. The second connecting member is configured to attach to a surface of the gas-ventilating member facing away from the inside of the battery cell. An orthographic projection of the first through hole on the gas-ventilating member and an orthographic projection of the second through hole on the gas-ventilating member are arranged to be staggered from each other.Type: ApplicationFiled: November 24, 2023Publication date: March 21, 2024Inventors: Wanqiu MENG, Qian LIU, Yonghuang YE, Yulian ZHENG, Longfei XUE, Xiaoxi ZHANG
-
Publication number: 20240084285Abstract: Provided is a method for producing a target DNA sequence and a cloning vector. The method includes the step of amplifying and extracting a DNA construct in a host cell, and a three-step thermostatic enzyme reaction step of protelomerase-IIS type restriction endonuclease and/or meganuclease-DNA exonuclease catalysis, wherein the construct is autonomously replicated and contains (a) one or more IIS type restriction endonuclease and/or meganuclease recognition sequences; (b) the target DNA sequence; and (c) protelomerase recognition sequences at lateral wings of two ends of the target DNA sequence.Type: ApplicationFiled: August 6, 2021Publication date: March 14, 2024Inventors: Lumeng YE, Haiye SUN, Qian GAO, Juan CHEN
-
Patent number: 11926982Abstract: An assembled subway station and a construction method thereof are provided. The assembled subway station includes a plurality of components combined in a ring shape, comprising a bottom plate component, two bottom corner components, two side wall components, a middle plate component, two top corner components, and a top plate component. Connection surfaces of each component are each provided with a concave-convex structure being matched with another concave-convex structure on a relevant connection surface of an adjacent component. Butt joint positions of two adjacent components are filled with sealing structures. The embedded grooves of two adjacent components are oppositely arranged, and connecting members for exerting opposite fastening forces on the two adjacent components are installed in the oppositely arranged embedded grooves.Type: GrantFiled: January 17, 2022Date of Patent: March 12, 2024Assignee: Guangzhou Metro Design & Research Institute Co., Ltd.Inventors: Xianli Ding, Bao Xiang, Xingzhong Nong, Juyang Wu, Haiou Shi, Feiqi Ou, Zihui Zan, Ran Wang, Shengya He, Xiao Li, Chunjie Liu, Liang Ye, Qian Zhou, Hengyi Li, Wenqi Zhang, Yiheng Ren, He Huang
-
Publication number: 20240069369Abstract: A display device and a dimming device are provided. A dimming layer is located between a first polarizer and a second polarizer whose transmission axes are parallel to each other. When the display device is in a first display mode, long axes of the liquid crystal molecules distributed in the first polymer network are arranged along the second direction, and long axis of the liquid crystal molecules distributed in the second polymer network are arranged along the third direction. The third direction and the second direction respectively point to opposite sides of a normal line of the first polarizer.Type: ApplicationFiled: December 22, 2021Publication date: February 29, 2024Applicant: Wuhan China Star Optoelectronics Technology Co., Ltd.Inventors: Rui HE, Xindong MEI, Wenlong YE, Qian DENG, Wei CHENG
-
Publication number: 20230394191Abstract: This disclosure provides techniques for automatically generating a geometric representation based on a system-level model (e.g., a lumped parameter model, or LPM). The geometric representation may include a three-dimensional (3D) or cross-sectional shape, resulting from topology optimization within a design space automatically generated without human intervention. An example method may include identifying one or more constraints for each of two or more components of an LPM. One or more conditions are generated for the LPM. The one or more conditions are mapped to the one or more constraints. A processing device may generate a design space for a geometric representation to perform functions represented by the LPM. The geometric representation is subject to the generated one or more conditions. The processing device may then perform topology optimization of the geometric representation in the design space to generate an optimized geometry (e.g., a converged and/or final output).Type: ApplicationFiled: June 2, 2022Publication date: December 7, 2023Inventors: Randi Wang, Anurag Bhattacharyya, Qian Ye, Clinton Morris, Amirmassoud Mirzendehdel, Morad Behandish
-
Publication number: 20230355759Abstract: Provided herein are populations of placental-derived natural killer cells comprising a cleavage resistant CD16. Also provided are methods of treating diseases, disorders or conditions in a human subject comprising administering to the subject an effective amount of a population of placental-derived natural killer cells comprising a cleavage resistant CD16 to the subject so as thereby to provide an effective treatment of the to the subject. The cells, such as CYNK cells, can be placental CD34+ cell-derived natural killer (NK) cells. The diseases, disorders or conditions include cancers such as multiple myeloma and lymphoma. The present invention also provides compositions comprising populations of placental-derived natural killer cells comprising a cleavage resistant CD16 for the treatment of a subject and methods of their use.Type: ApplicationFiled: July 31, 2020Publication date: November 9, 2023Applicant: CELULARITY INC.Inventors: Xuan GUO, Srinivas SOMANCHI, Rohit MATHUR, Shuyang HE, Qian YE, Xiaokui ZHANG, Salvatore ROTONDO, Hemlata RANA, Weifang LING, James W. EDINGER, Robert J. HARIRI, Andrea DIFIGLIA
-
Publication number: 20230326155Abstract: The present disclosure provides techniques for automatically modifying shape features related to overhangs such that support structures can be reduced or avoided. In an example, a shape modification processing device may obtain an initial shape and relevant production information (e.g., overhang angle threshold). The shape modification processing device may modify the shape to improve various aspects of production, including reduction or removal of the need for support materials or structures during additive manufacturing, with considerations that allow the modified portion (e.g., added features) be accessible for removal by subtractive manufacturing. For example, the shape modification processing device may modify a model to reduce or remove support structures needed during production. The added features may later be removed by subtractive manufacturing to restore any functional or desired shape.Type: ApplicationFiled: April 7, 2022Publication date: October 12, 2023Inventors: Qian Ye, Matt Patterson, Amirmassoud Mirzendehdel, Morad Behandish
-
Publication number: 20230310319Abstract: Several approaches to produce, isolate, and characterize exosomes recovered from a cultivated placenta or a portion thereof are provided. The alternatives described herein facilitate the production, isolation, and characterization of exosomes, which can be used as biotechnological tools and therapeutics. Also provided herein are populations of exosomes derived from placenta organ culture or culture of portions of the placenta. Also provided are compositions comprising the populatons of exosomes and methods of their use for the treatment of subjects.Type: ApplicationFiled: June 2, 2023Publication date: October 5, 2023Applicant: Celularity Inc.Inventor: Qian YE
-
Patent number: 11723930Abstract: Provided herein are methods of treatment of individuals having an immune-related disease, disorder or condition, for example, inflammatory bowel disease, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis, psoriasis, lupus erythematosus, diabetes, mycosis fungoides (Alibert-Bazin syndrome), or scleroderma using placental stem cells or umbilical cord stem cells.Type: GrantFiled: January 24, 2020Date of Patent: August 15, 2023Inventors: James W. Edinger, Robert J. Hariri, Jia-Lun Wang, Qian Ye, Herbert Faleck
-
Publication number: 20230210909Abstract: Provided herein are methods of using CD10+, CD34?, CD105+, CD200+ tissue culture plastic-adherent placental cells, e.g. placental stem cells, in the treatment of SARS-CoV-2 related acute respiratory failure and ARDS (COVID-19).Type: ApplicationFiled: May 10, 2021Publication date: July 6, 2023Applicant: Celularity Inc.Inventors: Robert J. HARIRI, Xiaokui ZHANG, Shuyang HE, Kathy KARASIEWICZ-MENDEZ, Qian YE, Tanel MAHLAKOIV, Stacy HERB, Corey CASPER
-
Publication number: 20230181649Abstract: The present invention provides method of treating diseases, disorders and conditions in a human subject comprising administering to the subject a population of exosomes or a composition comprising a population of exosomes, wherein said population of exosomes is positive for CD1c, CD20, CD24, CD25, CD29, CD2, CD3, CD8, CD9, CD11c, CD14, CD19, CD31, CD40, CD41b, CD42a, CD44, CD45, CD49e, CD4, CD56, CD62P, CD63, CD69, CD81, CD86, CD105, CD133-1, CD142, CD146, CD209, CD326, HLA-ABC, HLA-DRDPDQ, MCSP, ROR1, SSEA-4, or combinations thereof. Such diseases, disorders and conditions include lung, liver, central nervous system, kidney, cardiovascular, gastrointestinal, spleen, eye, systemic and ageing associated diseases, disorders, and conditions.Type: ApplicationFiled: June 19, 2020Publication date: June 15, 2023Applicant: Celularity Inc.Inventors: Robert J. HARIRI, Xiaokui ZHANG, Qian YE, Bhavani STOUT, Haley M. HARIRI, Navjot SHAH, Srinivas Somanchi, Shuyang He
-
Patent number: 11579158Abstract: An automatic human urine detection system comprises a control module, a urine collection module, a detection module, an output module and a cleaning module. The control module controls operation of the system and comprises an instruction input unit. The urine collecting module is used for collecting urine to be detected; the detection module comprises a detection probe holder which is used for detecting the urine to be collected and obtains a corresponding detection report according to a detection result; the output module is used for outputting the detection report; and the cleaning module is used for cleaning system components through which the urine flows or is stored in the system. The automatic human urine detection system integrates automatic collection and subsequent automatic detection of human urine, the whole urinalysis process is effectively simplified, the operation process is humanized, and the user experience is good.Type: GrantFiled: July 9, 2020Date of Patent: February 14, 2023Assignee: ZHEJIANG DEYEETEC MEDICAL TECHNOLOGY CO., LTD.Inventor: Zhi Qian Ye
-
Publication number: 20220348875Abstract: Provided herein are genetically modified (GM) natural killer (NK) cells and methods of producing populations of GM NK cells. Further provided herein are methods of using the GM NK cells described herein, to, e.g., suppress the proliferation of tumor cells, or to inhibit pathogen infection, e.g., viral infection. In certain alternatives, GM NK cells provided herein lack expression of CBLB, NKG2A and/or TGFBR2 and/or function or show reduced expression and/or function of CBLB, NKG2A and/or TGFBR2. In certain alternatives, GM NK cells provided herein comprise modified CD16.Type: ApplicationFiled: December 17, 2021Publication date: November 3, 2022Applicant: Celularity Inc.Inventors: Xiaokui Zhang, Qian Ye, Tianjian Li, Chuan Wang, Mini Bharathan, Uri Herzberg, Robert J. HARIRI
-
Publication number: 20220160787Abstract: The present invention provides an isolated non-human placenta derived stem cell, wherein the stem cell expresses CD90 or wherein the stem cell expresses CD29. The present invention also provides a composition comprising an isolated non-human placenta derived stem cell of the invention or a population of isolated non-human placenta derived stem cells of the invention, and a carrier. The present invention also provides a composition of the invention for use in the manufacture of a medicament to reduce the incidence of rejection in a patient receiving a xenotransplant form a non-human donor. The present invention provides a method of treating a subject receiving a xenotransplant or xenotransfusion comprising the step of administering to the patient an effective amount of a non-human placenta derived stem cells.Type: ApplicationFiled: March 16, 2020Publication date: May 26, 2022Applicant: Celularity Inc.Inventors: QIAN YE, Joseph GLEASON, Lin KANG, Robert J. HARIRI, Shuyang HE, Xiaokui ZHANG, Valentina ROUSSEVA
-
Publication number: 20220096352Abstract: The present invention provides compositions comprising human placental telopeptide collagen, methods of preparing the compositions, methods of their use and kits comprising the compositions. The compositions, kits and methods are useful, for example, for augmenting or replacing tissue of a mammal.Type: ApplicationFiled: May 13, 2021Publication date: March 31, 2022Applicant: Celularity Inc.Inventors: Mohit B. BHATIA, Chris LUGO, Qian YE, James W. EDINGER
-
Publication number: 20220096564Abstract: Provided herein are methods of using adherent placental stem cells and placental stem cell populations, and methods of culturing, proliferating and expanding the same. Also provided herein are methods of differentiating the placental stem cells. Further provided herein are methods of using the placental stem cells to formulate implantable or injectable compositions suitable for administration to a subject. Still further provided herein are provides methods for treating bone defects with stem cells and compositions comprising stem cells.Type: ApplicationFiled: May 13, 2021Publication date: March 31, 2022Applicant: Celularity Inc.Inventors: James W. EDINGER, Robert J. HARIRI, Jia-Lun WANG, Qian YE, Kristen S. LABAZZO, Marian PEREIRA, Sasha Dawn ABRAMSON
-
Publication number: 20210221854Abstract: This disclosure describes a system for generating influenza virus or influenza virus proteins, methods of making that system, and methods of using that system.Type: ApplicationFiled: January 15, 2021Publication date: July 22, 2021Inventors: Wei-Shou Hu, Thu Phan, Christopher S. Stach, Ryan A. Langlois, Qian Ye
-
Publication number: 20210145872Abstract: Provided herein are methods for forming three-dimensional tissues in vivo. In one embodiment, provided herein is a method for forming a three-dimensional tissue in vivo, comprising depositing on a surface that is in or on a subject at least one composition that comprises cells. In another embodiment, provided herein is a method for forming a three-dimensional tissue in vivo, comprising depositing on a surface that is in or on a subject at least one composition that comprises cells and at least one composition that comprises an extracellular matrix (ECM). In another embodiment, provided herein is a method for forming a three-dimensional tissue in vivo, comprising depositing on a surface that is in or on a subject at least one composition that comprises cells, at least one composition that comprises an extracellular matrix (ECM), and at least one other additional components.Type: ApplicationFiled: June 23, 2020Publication date: May 20, 2021Applicant: Celularity Inc.Inventors: Robert J. HARIRI, Mohit B. BHATIA, Wolfgang HOFGARTNER, Jia-Lun WANG, Qian YE
-
Publication number: 20210018525Abstract: An automatic human urine detection system comprises a control module, a urine collection module, a detection module, an output module and a cleaning module. The control module controls operation of the system and comprises an instruction input unit. The urine collecting module is used for collecting urine to be detected; the detection module comprises a detection probe holder which is used for detecting the urine to be collected and obtains a corresponding detection report according to a detection result; the output module is used for outputting the detection report; and the cleaning module is used for cleaning system components through which the urine flows or is stored in the system. The automatic human urine detection system integrates automatic collection and subsequent automatic detection of human urine, the whole urinalysis process is effectively simplified, the operation process is humanized, and the user experience is good.Type: ApplicationFiled: July 9, 2020Publication date: January 21, 2021Inventor: Zhi Qian YE
-
Patent number: D938511Type: GrantFiled: November 18, 2020Date of Patent: December 14, 2021Assignee: Wenzhou Yijie Trading Co., Ltd.Inventor: Qian Ye